Citadel Advisors
EDVA

Citadel Advisors’s Endovia Health Sciences, Inc. EDVA Stock Holding History

Citadel Advisors’s Portfolio EDVA Stock Details EDVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2
Closed -$48 – 15433
2024
Q4 		$48 Buy
2
+1
+100% +$33 ﹤0.01% 14392
2024
Q3 		$50 Sell
1
-4
-80% -$201 ﹤0.01% 14102
2024
Q2 		$184 Sell
5
-1
-17% -$47 ﹤0.01% 14074
2024
Q1 		$414 Buy
6
+4
+200% +$319 ﹤0.01% 14338
2023
Q4 		$166 Sell
2
-1
-33% -$95 ﹤0.01% 14108
2023
Q3 		$236 Sell
3
-167
-98% -$21.6K ﹤0.01% 14122
2023
Q2 		$30.5K Sell
170
-11
-6% -$2.01K ﹤0.01% 12340
2023
Q1 		$47.4K Buy
181
+80
+79% +$15.9K ﹤0.01% 12225
2022
Q4 		$15.6K Sell
101
-121
-55% -$21.2K ﹤0.01% 13317
2022
Q3 		$49K Buy
+222
New +$84.2K ﹤0.01% 11653

Other funds holding EDVA

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
PM
Phraction Management Colchester, Connecticut $596M AUM 36.77% 1-Year Est. Return
STA
Summit Trail Advisors New York $7.95B AUM 26.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $171M AUM
CFM
Compass Financial Management Tampa, Florida $829M AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Citadel Advisors's EDVA Position: Q2 2026 in Review

Citadel Advisors sold out of Endovia Health Sciences, Inc. (EDVA) in Q2 2026, closing a stake of 4,146 shares — an estimated $5.96K sold.

Citadel Advisors first reported a position in EDVA in Q2 2022 and held it in 10 quarters. The position peaked at $206K in Q4 2022. 18 funds tracked by Wall St. Rank hold EDVA as of Q2 2026.

  • Citadel Advisors reported no remaining Endovia Health Sciences, Inc. position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 4,146 Endovia Health Sciences, Inc. shares in Q2 2026, an estimated $5.96K.
  • Citadel Advisors first reported a position in Endovia Health Sciences, Inc. in Q2 2022 and held it in 10 quarters.
  • Citadel Advisors's Endovia Health Sciences, Inc. position peaked at $206K in Q4 2022.
  • 18 funds tracked by Wall St. Rank held Endovia Health Sciences, Inc. as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.